← brief for 2026-10-22 · Slowing decline

Meta-analysis of the effect of nafamostat mesilate versus no-anticoagulation regimens in adult patients undergoing continuous renal replacement therapy

Key takeaways

This review combined data from multiple studies on a blood thinner called nafamostat mesilate. It is used during a type of dialysis called continuous renal replacement therapy. The review found that this drug is a safe option for patients who are at high risk of bleeding.

Who did this work

Yao Wang (University of Electronic Science and Technology of China) · Xiaoli Du (University of Electronic Science and Technology of China) · Dan Wen (University of Electronic Science and Technology of China) · Rong Xu (University of Electronic Science and Technology of China) · Xiao Yu (University of Electronic Science and Technology of China) · Lingning Zhao (University of Electronic Science and Technology of China)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-10-21
https://doi.org/10.3389/fmed.2026.1984576